Option Products Sample Clauses

The 'Option Products' clause defines the types of optional goods or services that may be made available under the agreement, in addition to any core products already specified. This clause typically outlines the conditions under which these optional products can be selected, such as through written notice or an amendment, and may specify pricing, delivery terms, or limitations on availability. Its core practical function is to provide flexibility for the parties to expand or modify the scope of their relationship without renegotiating the entire contract, thereby accommodating evolving needs or preferences over time.
Option Products. (a) At any time during the Collaboration Term after the completion of research activities under a Validation Research Plan, either Ultragenyx or Takeda may, through the JRC, nominate a Candidate Product for selection as an Option Product, and the JRC will promptly consider such request. In order for a Candidate Product to become an Option Product, the JRC must agree (by mutual agreement of the Parties’ representatives on the JRC) to (i) the selection of the Candidate Product as an Option Product, (ii) a research plan, and budget that identifies the research and development activities which shall be performed and paid for entirely by Ultragenyx (each, an “Option Product Research Plan”), and (iii) key terms, including the territory, field of use, development and commercial responsibilities and financial terms (the “Option Product Key Terms”) to serve as the basis for an Option Product License Agreement. For clarity, the Option Product Research Plan for [***] Products is the [***] Research Plan. (b) The [***] Products are designated as Option Products as of the Effective Date. The Option Product Key Terms for [***] Products are attached hereto as Exhibit 6.10(b).
View SourceView Similar (2)
Option Products. Option Products" means Rambus Processors, Rambus --------------- Peripherals, and Rambus Customer Designed ASICs.
View SourceView Similar (2)
Option Products. At any time during the Collaboration Term after the completion of research activities under a Validation Research Plan, either Ultragenyx or Takeda may, through the JRC, nominate a Candidate Product for selection as an Option Product, and the JRC will promptly consider such request. In order for a Candidate Product to become an Option Product, the JRC must agree (by mutual agreement of the Parties’ representatives on the JRC) to (i) the selection of the Candidate Product as an Option Product, (ii) a research plan, and budget that identifies the research and development activities which shall be performed and paid for entirely by Ultragenyx (each, an “Option Product Research Plan”), and (iii) key terms, including the territory, field of use, development and commercial responsibilities and financial terms (the “Option Product Key Terms”) to serve as the basis for an Option Product License Agreement. For clarity, the Option Product Research Plan for [***] Products is the [***] Research Plan.
View SourceView Similar (2)
Option Products. (a) If Goldstar exercises the Option Right, within thirty (30) days after Rambus' receipt of the payment specified in Section 4.1(b)(i) below Rambus shall deliver to Goldstar one copy of the complete, most up-to-date versions of the then current revisions of the items listed in Exhibit C. (b) If Goldstar exercises the Option Right, from time to time Rambus will provide to Goldstar updates to the specifications listed in Exhibit C, if required to enable Goldstar to maintain Compatibility. In addition, Rambus will provide to Goldstar any corrections or other modifications to the design information listed in Exhibit C which are required to enable Goldstar to comply with the Rambus ASIC product specification provided by Rambus. This does not include any modifications pertaining to additional features or other modifications or additions to the product specification.
View SourceView Similar (2)
Option Products. With respect to the Option Products, --------------- including for the purposes of this Section 12.1, any product developed by SANO within ten years of the Effective Date which is a generic version of an existing marketed transdermal drug, PPI shall have the option, in its sole and absolute discretion, to include such products, on a product-by- product basis, as Licensed Products hereunder, in accordance with the following provisions.
View Source
Option Products. Incyte shall pay to Agenus royalties on Net Sales of each Option Product, on an Option Product-by-Option Product basis, in each Calendar Year as follows: The portion less than or equal to [**] [**] The portion greater than [**] and less than or equal to [**] [**] The portion greater than [**] and less than or equal to [**] [**] The portion greater than [**] [**]
View Source
Option Products 
View Source

Related to Option Products

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Other Products If you ask, we will provide you with information on any other home equity products we offer.